# A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

> **NCT02610062** · PHASE1 · TERMINATED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** AGS67E

## Key facts

- **NCT ID:** NCT02610062
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-29
- **Primary completion:** 2017-09-22
- **Final completion:** 2017-11-21
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Business decision by sponsor
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02610062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02610062, "A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02610062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*